Skip to main content

Table 1 Significant pathways from top 250 predictor genes associated with response to PG-11047 treatment using Ingenuity Pathway analysis.

From: A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047

Pathway Name P-Value Ratio Component genes in the pathway
Interferon Signaling 0.001 [4/29] IRF1, IRF9, TAP1, IFNGR1
Ephrin Receptor Signaling 0.011 [8/193] CXCR4, ABI1, RAP1A, MAPK1, WASL,
MAP4K4, GNAI3, PAK1
Role of BRCA1 in DNA Damage
Response
0.013 [4/52] RPA1, RFC3, MSH2, E2F3
Nicotinate and Nicotinamide
Metabolism
0.019 [5/129] NNMT, ENPP2, MAPK1, ENPP1, PAK1
Fcy Receptor -mediatedPhagocytosis in Macrophages andMonocytes 0.028 [5/104] RPS6KB1, LYN, MAPK1, VAMP3, PAK1
Riboflavin Metabolism 0.032 [2/49] ENPP2, ENPP1
Endoplasmic Reticulum Stress
Pathway
0.041 [2/18] XBP1, TAOK3
Pantothenateand CoA Biosynthesis 0.046 [2/63] ENPP2, ENPP1
CXCR4 Signaling 0.052 [6/164] CXCR4, RHOB, LYN, MAPK1, GNAI3, PAK1
PI3K/AKT Signaling 0.055 [5/135] RPS6KB1, SFN, MAPK1, YWHAH, PPP2R5A
Integrin Signaling 0.056 [7/198] RHOB, RAP1A, MAPK1, TSPAN6, WASL, ARF4, PAK1
  1. Ratio indicates the number of genes in the top 250 predictors that belong to the pathway indicated over the number of genes known of the pathway. Genes in bold were associated with resistance when transcribed at high levels. Genes in normal fonts were associated with sensitivity when transcribed at high levels.